Literature DB >> 11292998

Cardiovascular risk in women with polycystic ovary syndrome.

E O Talbott1, J V Zborowski, K Sutton-Tyrrell, K P McHugh-Pemu, D S Guzick.   

Abstract

Compared with normal cycling women of similar age, women with polycystic ovary syndrome (PCOS) have an adverse lipid profile and an increased prevalence of Type II diabetes and hypertension. These woman also appear to have greater subclinical atherosclerotic disease, as demonstrated by greater carotid intimamedia wall thickness and higher levels of coronary calcification. Given the high prevalence of PCOS in the female population, this condition may potentially account for a significant proportion of the atherosclerotic heart disease observed in younger women. This article reviews the issues and uncertainties surrounding the PCOS-CHD association.

Entities:  

Mesh:

Year:  2001        PMID: 11292998     DOI: 10.1016/s0889-8545(05)70189-3

Source DB:  PubMed          Journal:  Obstet Gynecol Clin North Am        ISSN: 0889-8545            Impact factor:   2.844


  12 in total

1.  Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile.

Authors:  E Zulian; P Sartorato; S Benedini; G Baro; D Armanini; F Mantero; C Scaroni
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

Review 2.  Gender differences in the cardiovascular effect of sex hormones.

Authors:  Cristiana Vitale; Michael E Mendelsohn; Giuseppe M C Rosano
Journal:  Nat Rev Cardiol       Date:  2009-06-30       Impact factor: 32.419

Review 3.  Targets to treat metabolic syndrome in polycystic ovary syndrome.

Authors:  Shruthi Mahalingaiah; Evanthia Diamanti-Kandarakis
Journal:  Expert Opin Ther Targets       Date:  2015-10-21       Impact factor: 6.902

4.  Risk of cardiovascular events in patients with polycystic ovary syndrome.

Authors:  S Iftikhar; M L Collazo-Clavell; V L Roger; J St Sauver; R D Brown; S Cha; D J Rhodes
Journal:  Neth J Med       Date:  2012-03       Impact factor: 1.422

5.  C-reactive protein and lipoprotein-a as markers of coronary heart disease in polycystic ovary syndrome.

Authors:  Nilgün Güdücü; Herman Işçi; Alin Başgül Yiğiter; Ilkkan Dünder
Journal:  J Turk Ger Gynecol Assoc       Date:  2012-12-01

6.  Comparison of Biomedical Variables in PCOS Patients with Normal Iranian Women.

Authors:  Maryam Bagheri; Farnaz Sohrabvand; Mahnaz Lankarani; Zahra Zandieh; Fedyeh Haghollahi; Mamak Shariat
Journal:  J Family Reprod Health       Date:  2015-03

7.  Comparison of the Association of Excess Weight on Health Related Quality of Life of Women with Polycystic Ovary Syndrome: An Age- and BMI-Matched Case Control Study.

Authors:  Farnaz Shishehgar; Fahimeh Ramezani Tehrani; Parvin Mirmiran; Sepideh Hajian; Ahmad Reza Baghestani
Journal:  PLoS One       Date:  2016-10-13       Impact factor: 3.240

8.  Serum C-reactive protein levels in normal-weight polycystic ovary syndrome.

Authors:  Ji Young Oh; Ji-Ah Lee; Hyejin Lee; Jee-Young Oh; Yeon-Ah Sung; Hyewon Chung
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 2.884

9.  Anti-Inflammatory Dietary Combo in Overweight and Obese Women with Polycystic Ovary Syndrome.

Authors:  Amany Alsayed Salama; Ezzat Khamis Amine; Hesham Abd Elfattah Salem; Nesrin Kamal Abd El Fattah
Journal:  N Am J Med Sci       Date:  2015-07

Review 10.  Endothelial progenitor cell dysfunction in polycystic ovary syndrome: implications for the genesis of cardiovascular diseases.

Authors:  Yu-Hsun Kao; Wan-Chun Chiu; Ming-I Hsu; Yi-Jen Chen
Journal:  Int J Fertil Steril       Date:  2013-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.